Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 80Fluorouracil 75Oxaliplatin 67Magnetic Resonance Spectroscopy 61Leucovorin 59Bevacizumab 56Gemcitabine 53Biopsy 41Irinotecan 37Capecitabine 37pembrolizumab 35Cisplatin 35Nivolumab 33Cetuximab 32130-nm albumin-bound paclitaxel 28Paclitaxel 27durvalumab 26atezolizumab 21Folfox protocol 20Radiotherapy 17Carboplatin 17Taxes 16dehydroftorafur 15Radiation 14Cyclophosphamide 14X-Rays 13Albumin-Bound Paclitaxel 13trastuzumab deruxtecan 12fludarabine 12Surgical Procedures, Operative 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × Gastrointestinal × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡